Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Apotex Pays Out Over US Price-Fixing Claims

Deal Over Pravastatin Includes $24.1m Fine And Deferred Prosecution Agreement

Executive Summary

Apotex has agreed to pay a $24.1m fine and enter into a deferred prosecution agreement to resolve US price-fixing claims over the cholesterol-lowering drug pravastatin.

You may also be interested in...



Taro Penalties Exceed $400m As It Admits Fixing Prices With Sandoz

In the latest development arising from ongoing generic pricing investigations in the US, Taro has admitted to fixing prices, allocating customers and rigging bids for generic medicines, under a conspiracy with multiple firms, including Sandoz.

Teva Chosen As 'Bellwether' In US Price-Fixing Litigation

Litigation involving Teva has been selected as a “bellwether” case, making it a priority for trial as part of the ongoing US investigation into generic price-fixing.

Glenmark Pushes Back On US Price-Fixing Charges

Glenmark has issued a forceful rebuttal over US price-fixing charges being pursued by the country’s Department of Justice covering drugs such as pravastatin.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel